West Pharmaceutical Services (WST) Q1 2026 Earnings
How Did WST Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +5.95%.
Did WST Beat Earnings? Q1 2026 Results
Yes. West Pharmaceutical Services reported Q1 2026 earnings of $2.13 a share on Apr 23, 2026, beating the $1.68 consensus estimate by 27.1%. Revenue was $844.9M against a $779.4M estimate.
West Pharmaceutical Services kicked off fiscal 2026 with a strong first quarter, posting adjusted diluted EPS of $2.13 and revenue of $844.90 million, up 10.3% year over year, as surging demand for its High Value Product components and delivery devices powered broad-based growth. The Proprietary Products segment was the clear engine, climbing 23.3% to $694.30 million, with GLP-1-related elastomer revenues alone accounting for 10% of total company sales and West Vantage GLP-1 revenues contributing another 8%, cementing the company's deepening role in the fast-growing obesity and diabetes drug category. Gross margin expanded 190 basis points to 35.1% and adjusted operating margin widened 350 basis points to 21.4%, helped by a favorable mix shift toward higher-margin products and sharply lower restructuring charges. Barclays responded by lifting its price target to $310, citing the robust demand recovery. Encouraged by the momentum, management raised full-year 2026 adjusted EPS guidance to $8.40 to $8.75 and lifted the revenue outlook to $3.29 billion to $3.35 billion, reflecting 7% to 9% organic growth.
- Double-digit organic growth in both GLP-1 and non-GLP-1 HVP Components revenues
- Strong production ramp-up execution, especially in Europe
- Favorable mix shift toward higher-margin High Value Products
- Increased sales of self-injection device platforms for obesity and diabetes (West Vantage)
- Strong Crystal Zenith growth driven by biologics market
- Approximately 5.7 percentage points of favorable currency translation impact
“I am pleased to report a very strong start to the year with revenues and adjusted EPS exceeding expectations. Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues. The better-than-expected performance can be attributed to continued market demand and the team's outstanding efforts in ramping up production, especially in Europe. As a result of these excellent first quarter results and expected continued momentum in our business, we are increasing our full-year 2026 guidance.”
West Pharmaceutical Services CEO, on the earnings call
What Was West Pharmaceutical Services's Outlook in Q1 2026?
West raised full-year 2026 net sales guidance to $3.295B–$3.350B (from $3.215B–$3.275B), representing 7.2%–9.0% reported growth and 7%–9% organic growth, with an estimated 2 percentage point FX benefit. Full-year adjusted-diluted EPS guidance was increased to $8.40–$8.75 (from $7.85–$8.20), representing 15.2%–20.0% growth over 2025 actual of $7.29. Capital expenditure guidance remains $250M–$275M. For Q2 2026, net sales are expected at $830M–$850M (8.3%–10.9% reported growth, 7.0%–9.6% organic), with adjusted-diluted EPS of $2.05–$2.12. Guidance assumes a mid-year closing of the SmartDose 3.5mL sale to AbbVie. The estimated full-year tax rate is approximately 19%.
WST YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $844.9M | $766.2M | +10.3% |
| Gross Profit | $296.4M | $273.2M | +8.5% |
| Operating Income | $177.1M | $158.2M | +12.0% |
| Net Income | $138.8M | $131.8M | +5.3% |
WST Revenue by Segment
WST Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.